Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Reck, Martin [VerfasserIn]   i
 von Pawel, J. [VerfasserIn]   i
 Zatloukal, P. [VerfasserIn]   i
 Ramlau, R. [VerfasserIn]   i
 Gorbounova, V. [VerfasserIn]   i
 Hirsh, V. [VerfasserIn]   i
 Leighl, N. [VerfasserIn]   i
 Mezger, J. [VerfasserIn]   i
 Archer, V. [VerfasserIn]   i
 Moore, N. [VerfasserIn]   i
 Manegold, Christian [VerfasserIn]   i
Titel:Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer
Titelzusatz:results from a randomised phase III trial (AVAiL)
Verf.angabe:M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore, C. Manegold & BO17704 Study Group
E-Jahr:2010
Jahr:September 2010
Umfang:6 S.
Fussnoten:Elektronische Reproduktion der Druckausgabe ; Gesehen am 11.05.2023
Titel Quelle:Enthalten in: Annals of oncology
Ort Quelle:Amsterdam [u.a.] : Elsevier, 1990
Jahr Quelle:2010
Band/Heft Quelle:21(2010), 9 vom: Sept., Seite 1804-1809
ISSN Quelle:1569-8041
Abstract:Background - Bevacizumab, the anti-vascular endothelial growth factor agent, provides clinical benefit when combined with platinum-based chemotherapy in first-line advanced non-small-cell lung cancer. We report the final overall survival (OS) analysis from the phase III AVAiL trial. - Patients and methods - Patients (n=1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n=345), bevacizumab 15 mg/kg (n=351) or placebo (n=347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. - Results - Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64-0.87), P=0.0003 and 0.85 (0.73-1.00), P=0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78-1.11), P=0.420 and 1.03 (0.86-1.23), P=0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (∼62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. - Conclusions - Final analysis of AVAiL confirms the efficacy of bevacizumab when combined with cisplatin-gemcitabine. The PFS benefit did not translate into a significant OS benefit, possibly due to high use of efficacious second-line therapies.
DOI:doi:10.1093/annonc/mdq020
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1093/annonc/mdq020
 Volltext: https://www.sciencedirect.com/science/article/pii/S0923753419400471
 DOI: https://doi.org/10.1093/annonc/mdq020
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:bevacizumab
 chemotherapy
 NSCLC
 overall survival
 vascular endothelial growth factor
K10plus-PPN:184517898X
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69074757   QR-Code
zum Seitenanfang